Trial Profile
A Randomized, Double-Blinded, Placebo-Controlled, Multi-Institutional, Phase II.5 Study of Saracatinib (AZD0530), a Selective Src Kinase Inhibitor, In Patients With Recurrent Osteosarcoma Localized to the Lung.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 21 Jan 2020
Price :
$35
*
At a glance
- Drugs Saracatinib (Primary)
- Indications Cancer metastases; Osteosarcoma
- Focus Biomarker; Therapeutic Use
- 07 Jan 2020 Status changed from completed to discontinued.
- 07 Jan 2020 Status changed from completed to discontinued.
- 09 May 2018 Status changed from active, no longer recruiting to completed.